Literature DB >> 33978959

Pharmacokinetic study of an anti-trypanosome agent with different formulations and administration routes in mice by HPLC-MS/MS.

Yaxin Li1, Cody M Orahoske1, Raina Dano1, Wenjing Zhang1, Bibo Li2, Bin Su1.   

Abstract

Previously compound 12 showed great anti-trypanosome activity without toxicity in an in vivo study. In the current study, a sensitive and rapid high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated to investigate its pharmacokinetics in mouse plasma. A protein precipitation method was applied to extract the compound, and it was then separated using a Kinetex C18 column with mobile phase consisting of acetonitrile-0.1% formic acid water (50:50, v/v) at a flow rate of 300 μl/min. The analytes were detected with the multiple reaction monitoring in negative electrospray ionization source for quantitative response of the compounds. Compound 12 was detected at m/z 477.0 → 367.2, while the internal standard compound 14 was detected at m/z 499.2 → 268.2. Inter- and intra-day precision was <5.22 and 2.79% respectively, while the accuracy range was within ±9.65%. The method was successfully applied to evaluate the pharmacokinetics of compound 12 in mouse plasma with two formulations (20% Cremophor EL or sesame oil) and drug administration routes (oral and intraperitoneal injection). We observed a better drug serum concentration with the Cremophor formulation, and the two different drug administration routes did not show significant differences from the drug distribution.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Cremophor EL; HPLC-MS/MS; anti-trypanosome; pharmacokinetics; sesame oil

Mesh:

Substances:

Year:  2021        PMID: 33978959      PMCID: PMC8434948          DOI: 10.1002/bmc.5169

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.911


  16 in total

1.  Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers.

Authors:  Dvora Izgelov; Elyad Davidson; Dinorah Barasch; Aviva Regev; Abraham J Domb; Amnon Hoffman
Journal:  Eur J Pharm Biopharm       Date:  2020-07-04       Impact factor: 5.571

2.  In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release.

Authors:  Chan-Jung Li; Mei-Yun Ku; Chia-Yin Lu; Yu-En Tien; Wendy H Chern; Jin-Ding Huang
Journal:  Int J Pharm       Date:  2017-08-25       Impact factor: 5.875

3.  Lead optimization of dual tubulin and Hsp27 inhibitors.

Authors:  Bo Zhong; Rati Lama; Daniel G Kulman; Bibo Li; Bin Su
Journal:  Eur J Med Chem       Date:  2014-04-13       Impact factor: 6.514

Review 4.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Authors:  H Gelderblom; J Verweij; K Nooter; A Sparreboom
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

Review 5.  Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.

Authors:  Irina Cherniakov; Abraham J Domb; Amnon Hoffman
Journal:  Expert Opin Drug Deliv       Date:  2015-01-05       Impact factor: 6.648

6.  Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

Authors:  L van Zuylen; M O Karlsson; J Verweij; E Brouwer; P de Bruijn; K Nooter; G Stoter; A Sparreboom
Journal:  Cancer Chemother Pharmacol       Date:  2001-04       Impact factor: 3.333

7.  Effect of formulation on the pharmacokinetics and efficacy of doramectin.

Authors:  S R Wicks; B Kaye; A J Weatherley; D Lewis; E Davison; S P Gibson; D G Smith
Journal:  Vet Parasitol       Date:  1993-07       Impact factor: 2.738

8.  Review and analysis of FDA approved drugs using lipid-based formulations.

Authors:  Ronak Savla; Jeff Browne; Vincent Plassat; Kishor M Wasan; Ellen K Wasan
Journal:  Drug Dev Ind Pharm       Date:  2017-07-06       Impact factor: 3.225

Review 9.  Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis.

Authors:  Peter G E Kennedy; Jean Rodgers
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

10.  Orally Active and Selective Tubulin Inhibitors as Anti-Trypanosome Agents.

Authors:  Vishal Nanavaty; Rati Lama; Ranjodh Sandhu; Bo Zhong; Daniel Kulman; Viharika Bobba; Anran Zhao; Bibo Li; Bin Su
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.